The 85th Scientific Sessions of the American Diabetes Association brought together leaders in diabetes technology, unveiling significant developments and reinforcing ongoing momentum in the sector. While type 2 diabetes continued to receive major attention, innovations in continuous glucose monitoring (CGM), automated insulin delivery, and implantable systems signaled a broader evolution in care.
Many companies showcased the expansion of existing platforms to accommodate wider patient populations, alongside introductions of novel technologies, such as fully integrated all-in-one solutions and implantable CGMs. The trend points toward a future of seamless, user-friendly management for both type 1 and type 2 diabetes.
According to BTIG analysts Marie Thibault, Sam Eiber, and Alexandra Pang, the sector is preparing for major growth. Factors like broader insurance coverage, regulatory label expansions, and greater public awareness are driving acceleration. However, 2025 is seen as a foundational year, with the potential for real market disruption coming in 2026 and beyond.
Overall, the sentiment from ADA 2025 was clear: diabetes tech is advancing rapidly, laying the groundwork for the next generation of patient-centric, high-precision care.
Follow MEDWIRE.AI for the latest in diabetes technology breakthroughs.
